REDWOOD CITY, Calif., Aug. 21 /PRNewswire/ -- Codexis, Inc., a private biotechnology company, today announced the appointment of Thomas Daussmann, Ph.D., to the new position of Vice President and Managing Director of Codexis Laboratories Singapore Pte. Ltd. CLS is the company's first facility in Asia. Dr. Daussmann will report to Alan Shaw, Ph.D., President and CEO.
"We are very pleased to name Dr. Daussmann to this important new position on the Codexis senior management team," Dr. Shaw said. "Thomas has built a strong track record of accomplishment as managing director of Codexis' Julich Chiral Solutions subsidiary, and he is a widely-respected scientist in the field of biocatalysis. He will play an equally critical role in building the company's Asian research and development presence."
Since 1999, Dr. Daussmann has served as managing director of Julich Chiral Solutions, (previously JFC-Julich Fine Chemicals), the Codexis enzyme and intermediates manufacturing facility in Germany. JFC was acquired by Codexis in 2005. Dr. Daussmann has authored or co-authored more than 25 scientific publication articles on biocatalytic manufacturing, and is named on numerous patent applications in the field. He received his bachelor's degree in biology from the University of Karlsruhe, his master's degree in biotechnology from the University of Kaiserslautern, and his Ph.D. degree in microbiology from the Research Centre in Julich (all in Germany). His doctoral study was conducted under the supervision of Professor Christian Wandrey, University of Bonn, a respected authority in biotechnology research.
Build-out has begun on the 20,000-square-foot research center in the
Science Park III area of Singapore. It is scheduled to open this fall as an
expansion of Codexis U.S. research and development operations. CLS will be
able to house up to 80 research and operations personnel. Bio*One Capital
Pte. Ltd. of Singapore led the Codexis Series D private financing ro
|SOURCE Codexis, Inc.|
Copyright©2007 PR Newswire.All rights reserved